Evidence map›Paper›PMID 22555168›Full record

ArticleAIDS (London, England)2012

Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection.

Jason Grebely, Margaret Hellard, Tanya Applegate, Kathy Petoumenos, Barbara Yeung, Jordan J Feld, William Rawlinson, Andrew R Lloyd, Jacob George, John M Kaldor and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014
    Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Jason GrebelyThe Kirby Institute for Infection and Immunity in Society, University of New South Wales (UNSW), Sydney, Australia. jgrebely@kirby.unsw.edu.au
Margaret Hellard
Tanya Applegate
Kathy Petoumenos
Barbara Yeung
Jordan J Feld
William Rawlinson
Andrew R Lloyd
Jacob George
John M Kaldor
Gregory J Dore
Gail V Matthews
ATAHC Study Group
Institute of Infection and Immunity · CAUNSW Sydney · AUMillennium Institute · BRThe Alfred Hospital · AUToronto Western Hospital · CA

Funding

Treatment of recently acquired hepatitis C virus infectionR01DA015999 · NIDA · UNIVERSITY OF NEW SOUTH WALES · PI DORE, GREGORY JOHN · 2003 to 2014
$3.7M
NIDA NIH HHS R01 DA015999NIDA NIH HHS R01 DA 15999-01
6 · The paper itself

Abstract

objectiveThe role of ribavirin (RBV) in the treatment of recent hepatitis C virus (HCV) (acute/early chronic) is unclear, particularly in HIV-infected individuals. This study evaluated early virological decline during recent HCV therapy in HIV-uninfected individuals receiving pegylated interferon (PEG-IFN) monotherapy and HIV-infected individuals receiving PEG-IFN/RBV.

designThe Australian Trial in Acute Hepatitis C was a nonrandomized prospective study of patients with recent HCV.

methodsAll participants received PEG-IFN (24 weeks); HCV/HIV participants also received RBV. Early HCV RNA decline was assessed among adherent participants (≥80% PEG-IFN, ≥80% treatment). Logistic regression identified predictors of rapid virological response (RVR) (<10 IU/ml).

resultsOf 109 treated, 82% were adherent (HCV, n=57; HCV/HIV, n=32). Overall, RVR was 51% (HCV: 55% vs. HCV/HIV: 43%; P=0.323). Factors independently associated with RVR included duration of infection less than 26 weeks, HCV RNA below 5.6 log(10) IU/ml at baseline and HCV genotype 2/3 infection. Between baseline and week 12, mean decline in HCV RNA was greater in HCV/HIV participants (PEG-IFN/RBV) compared to HCV participants (PEG-IFN) (4.19 vs. 3.32 log(10) IU/ml; P=0.029). Greater HCV RNA decline was observed in those treated with RBV, particularly amongst those with an estimated duration of infection at least 26 weeks and those with unfavourable IL28B genotypes. Adherent HIV-uninfected and infected participants had similar early virological response (76 vs. 90%; P=0.102) and sustained virological response (63 vs. 75%; P=0.253), respectively. RVR was highly predictive of sustained virological response (adjusted odds ratio 4.09; 1.49, 11.25).

conclusionThe results of this study suggest a potential benefit for PEG-IFN and RBV combination therapy in maximizing virological responses in HCV/HIV participants with recent HCV, particularly those with a longer duration of HCV infection and unfavourable IL28B genotypes.

Indexed as

AdultAntiviral AgentsAustraliaCoinfectionFemaleGenotypeHepacivirusHepatitis CHIVHIV SeropositivityHumansInterferon-alphaInterferon LambdaInterferonsInterleukinsLogistic ModelsAntiviral AgentsInterferon-alphaInterferon Lambdainterferon-lambda, humanInterferonsInterleukinsRibavirinRNA, Viral

Identifiers

PMID22555168
PMCPMC4268003
OpenAlexW2016197096

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.